779 patents
Page 21 of 39
Utility
Glycoconjugation processes and compositions
7 Sep 21
The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
Jianxin Gu, Jin-hwan Kim, Avvari Krishna Prasad, Yu-ying Yang
Filed: 28 Jan 20
Utility
Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
7 Sep 21
Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
Filed: 1 Mar 17
Utility
Escherichia Coli Compositions and Methods Thereof
2 Sep 21
This invention provides a polypeptide derived from E. coli or a fragment thereof, including compositions and methods thereof.
Robert G.K. Donald, Rosalind Pan
Filed: 22 Feb 21
Utility
Pharmaceutical Aqueous Formulation Comprising 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA
2 Sep 21
The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution.
James Joseph Hussey, Andrew Gilbert Bright
Filed: 20 Aug 18
Utility
Solid State Forms of (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE and Uses Thereof
2 Sep 21
The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Elaine GREER, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
Filed: 19 Feb 21
Utility
Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
2 Sep 21
The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
Filed: 13 Oct 20
Utility
CDK2 Inhibitors
2 Sep 21
Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
Filed: 20 Apr 21
Utility
Kras G12C Inhibitors
2 Sep 21
The present invention relates to compounds that inhibit KRas G12C.
John P. FISCHER, Jay Bradford FELL, James F. BLAKE, Ronald Jay HINKLIN, Macedonio J. MEJIA, Erik James HICKEN, Mark Joseph CHICARELLI, John J. GAUDINO, Guy P.A. VIGERS, Laurence E. BURGESS, Matthew Arnold MARX, James Gail CHRISTENSEN, Matthew Randolf LEE, Pavel SAVECHENKOV, Henry J. ZECCA, Tony P. TANG
Filed: 17 May 17
Utility
Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases
31 Aug 21
Ronald Jay Hinklin, Shelley Allen, Patrick Barbour, Adam Cook, Joshua Dahlke, John Gaudino, Ellen Laird, Oren T. McNulty, Qian Zhao
Filed: 29 Aug 19
Utility
Treatment of imatinib resistant leukemia
31 Aug 21
The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.
Becker Hewes
Filed: 30 May 08
Utility
Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same
26 Aug 21
The present disclosure generally relates to nanoparticles comprising an endo-lysosomal escape agent, a nucleic acid, and a polymer.
Allen Thomas Horhota, Young-Ho Song, Ujjwal Chaitanya Joshi, Nicholas Jon Boylan, Matthew John Simmons
Filed: 18 Feb 21
Utility
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens, Kits Comprising the Same and Uses Thereof
26 Aug 21
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof.
Wendy Jo Watson, Luis Pascual Jodar Martin-Montalvo, Raul Enrique Isturiz, Ralf Rene Reinert
Filed: 27 Apr 21
Utility
CDK2 Inhibitors
26 Aug 21
Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
Filed: 20 Apr 21
Utility
Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrile
24 Aug 21
Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
Filed: 16 Jun 20
Utility
Methods of Treating Cancer Using Combination Therapy
19 Aug 21
The present application is directed to therapeutic regimens and methods of treating cancer, with the regimens and methods comprising administering to the subject a programmed death-ligand 1 (PD-L1) inhibitor and a recombinant vesicular stomatitis virus that has been engineered to expresses interferon beta (VSV-IFNβ-NIS).
Stephen J. Russell, Alice Bexon, Kah-Whye Peng, Rose Marie Diaz
Filed: 21 Jun 19
Utility
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
17 Aug 21
The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof.
Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
Filed: 12 Jun 20
Utility
Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
17 Aug 21
Qian Zhao, Stacey Spencer, Yutong Jiang, Julia Haas, Charles Todd Eary
Filed: 26 Oct 17
Utility
Anti-e-selectin Antibodies, Compositions and Methods of Use
12 Aug 21
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin.
James Reasoner Apgar, Sheryl Rubio Bowley, Joanne Elizabeth-Ayriss Elwell, Laura Lin, Jatin Narula, Chuenlei Parng, Debra Denene Pittman, Swapnil Rakhe, Chihyi Vincent Yu
Filed: 21 Jan 21
Utility
Non-lipidated variants of
3 Aug 21
The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof.
Annaliesa Sybil Anderson, Kathrin Ute Jansen, Mark Edward Ruppen, Justin Keith Moran, Susan Kay Hoiseth
Filed: 10 Oct 19
Utility
Crystalline forms of lorlatinib maleate
3 Aug 21
This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile(lorlatinib) maleate.
Klimentina Dimitrova Pencheva
Filed: 27 Mar 17